Cellacare Genucast 0° Classic Knieorthese Immobilisierung mit anpassbaren Aluminiumstäben

Cellacare Genucast 0° Classic Knieorthese Immobilisierung mit anpassbaren Aluminiumstäben

Marsoni

M251S

$96.34

Get it in 3 business days with 1 day shipping. Friday, May 29

Cellacare Genucast 0° Classic Knieorthese Immobilisierung mit anpassbaren Aluminiumstäbenzur Immobilisierung des Kniegelenks anformbare Aluminiumstbe untersttzen bewhrtes Funktionsprinzip und guter Tragekomfort sichere Fixierung der Orthese durch Klettbnder waschbar bei 30 Grad

Easy Shipping

Quick Dispatch:

Your Cellacare Genucast 0° Classic Knieorthese Immobilisierung mit anpassbaren Aluminiumstäben orders ship within 1-2 business days.

Delivery Options:

Standard: 3-7 business days
Fast: 2-3 business days
Express: 1-2 business days

Order Tracking:

You'll receive a tracking link by email once your Cellacare Genucast 0° Classic Knieorthese Immobilisierung mit anpassbaren Aluminiumstäben ships.

Need Help?
Questions about Cellacare Genucast 0° Classic Knieorthese Immobilisierung mit anpassbaren Aluminiumstäben, sizing, or delivery? We're just an email away.

Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for Cellacare Genucast 0° Classic Knieorthese Immobilisierung mit anpassbaren Aluminiumstäben in your area.

Get Shipping Estimates

Country Zip/Postal Code

Exchange/Return Notes

We offer a 30-day return/exchange service after receiving.
Final sale items are not eligible for returns or exchanges.
To process your return/exchange, please contact us at [email protected]
Please click here for more details>>> Return & Exchange Policy

I love this mat. I use it 5x per week with my strength training, cardio, stretching, whaever workouts. I prefer to be barefoot on it. It’s holding up well and is easy to roll up and store when not in use. I like the size, it gives me enough room to do whatever workout I need to do. The green color is very cute too! I’m 5’3”

WAS THIS REVIEW HELPFUL?YesReportShare

Reviewed in the United States on April 28, 2026